Clinical Trials
13 trialsNCT03437941 2026-05-15
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Phase 1/2 Terminated
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT07336446 2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2 Recruiting
NCT04090528 2025-12-05
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT02294461 2025-10-24
An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants
Astellas Pharma Inc
Phase 3 Completed
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03050866 2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2 Unknown
NCT03478904 2021-05-10
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02162836 2020-04-27
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT00878436 2018-02-07
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
NYU Langone Health
Phase 1/2 Completed
NCT00918385 2014-10-29
ARS
Duke University
Phase 2 Terminated
NCT01351688 2013-07-03
An Open Label Prostate Cancer Study in Japanese Patients
AstraZeneca
Phase 1 Completed
NCT01337518 2012-12-18
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
Enzon Pharmaceuticals, Inc.
Phase 1 Suspended